Five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) Meeting Abstract
| Authors: | Ansell, S.; Bröckelmann, P.; von Keudell, G.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Collins, G.; Cohen, J.; De Boer, J. P.; Kuruvilla, J.; Savage, K.; Trněný, M.; Provencio, M.; Jaeger, U.; Willenbacher, W.; Swanink, R.; Shipp, M.; Engert, A.; Armand, P. |
| Abstract Title: | Five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | immunotherapy; classical hodgkin lymphoma; nivolumab; checkpoint inhibitor; hl |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S373 |
| End Page: | S374 |
| Language: | English |
| ACCESSION: | WOS:000691910500292 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01854-1 |
| Notes: | Meeting Abstract: HL-398 -- Source: Wos |
